3 Reasons Why Leading CROs & Pharma Companies are Choosing Us for COVID-19 Studies

There are many EDC platforms available today, but not all can handle the scale, complexity, and urgency of pandemic-era trials. To succeed, Pharma and Contract Research Organizations (CROs) need solutions they can depend on.

With COVID-19 disrupting lives and economies across the world, all eyes turned to pharmaceutical companies to find a solution. These organizations raced to develop vaccines that could slow down and eventually eradicate the pandemic. It’s hard to recall another time when vaccine development dominated global headlines and political discussions. With such immense pressure, pharma companies need the most reliable and efficient solutions to achieve their goals.

Over the past six months, Clinion has been actively supporting CROs and pharmaceutical companies with our integrated eClinical platform. As we began enabling several COVID-19 vaccine and therapeutic studies, we extended our learnings to other ongoing and new studies.

We are currently:

• Helping six different companies conduct clinical trials for vaccines and medicines
• Supporting more than 13 studies across the world
• Partnering with Bharat Biotech to conduct clinical trials for COVAXIN

Setting up one study involving over 15,000 subjects

Here are some reasons why Bharat Biotech chose Clinion’s Integrated Platform to manage their clinical trials.

Tried and Tested Solution

This is not the time for CROs to experiment with new systems. With so much at stake, CROs look for proven, stable, and widely trusted platforms. Many leading CROs such as JSS, CBCC, and Clinnex use Clinion’s platform, having run numerous studies smoothly and successfully.

These organizations find our solution scalable and robust enough to handle large study groups, while also being intuitive and easy to learn.

Time Sensitive

This is perhaps the most critical factor in COVID-19 studies. Studies have gone live on Clinion in just 10 days, whereas most other platforms take three weeks or more. Having supported over 250 studies, our experience has enabled us to build a platform that is intuitive, user-friendly, and capable of rapid study setup without compromising on accuracy or compliance.

Cost Effective

CROs also look for cost-effective solutions. Our platform includes all key components required for COVID-19 studies under a single license, along with multiple tightly integrated modules. This allows CROs and pharma companies to pay only for what they need while maintaining full functionality across their studies.

CROs across India and abroad have long been using EDC systems and are familiar with their benefits. However, the true advantages of a fully integrated eClinical platform are still being realized. Below are some of the key benefits.

Integrated EDC & IWRS

Randomization is a vital component of clinical trials. Clinion’s integrated IWRS enables quick setup of complex randomization studies with minimal effort. Since it integrates seamlessly with the EDC, data can flow securely between the two systems, improving efficiency and reducing manual intervention.

Integrated EDC & CTMS

A CTMS provides a holistic view of study performance and enables sponsors to track progress and manage resources effectively. Clinion’s CTMS consolidates multiple data points, including:

• Subject Recruitment Status
• Project Planning and Management
• Site Monitoring
• Document Management System
• Study Safety Reporting

By integrating CTMS with EDC, sponsors and CROs can access real-time study data, manage investigational product (IP) efficiently, and track budgets and expenses with greater transparency.

Integrated eConsent & eCOA

Subject consent is a critical regulatory requirement. With Clinion’s mobile app-based eConsent, CROs can onboard participants virtually, a capability that proved invaluable during COVID-19 studies.

Additionally, Clinion eCOA enables remote data collection from patients using their own devices. The data synchronizes directly with the EDC, allowing site personnel to monitor and review patient data in real time.

While Indian pharma companies and CROs have the expertise and talent to develop vaccines, they deserve strong support from their technology partners.

Clinion’s integrated, AI-enabled eClinical platform empowers CROs and sponsors to conduct faster, safer, and more efficient clinical trials, even in challenging times.

For a demo of our products, please contact us at sales@clinion.com.